Document Detail


Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
MedLine Citation:
PMID:  15642562     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Coronary Drug Project, conducted during 1966 to 1974, was a randomized, double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men with previous myocardial infarction. Among the 5 drug treatment regimens, only niacin significantly reduced the risk of (1) cardiovascular events during a mean follow-up of 6.2 years and (2) total mortality during 6.2 years with study treatment plus an additional 9 years of post-trial follow-up (Figure 1). Cardiovascular and total mortality outcomes in the niacin and placebo groups are presented by baseline glycemic status and by change in glycemic status from baseline to year 1.
Authors:
Paul L Canner; Curt D Furberg; Michael L Terrin; Mark E McGovern
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  95     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-11     Completed Date:  2005-02-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  254-7     Citation Subset:  AIM; IM    
Affiliation:
Maryland Medical Research Institute, 600 Wyndhurst Avenue, Baltimore, MD 21210, USA. plcanner@juno.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / administration & dosage*
Blood Glucose / metabolism
Florida / epidemiology
Follow-Up Studies
Humans
Male
Maryland / epidemiology
Myocardial Infarction / drug therapy*,  mortality*
Niacin / administration & dosage*
North Carolina / epidemiology
Proportional Hazards Models
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Blood Glucose; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in pa...
Next Document:  Occurrence of acute myocardial infarction in Worcester, Massachusetts, before, during, and after the...